Kei S. Tolliver

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.

S&R Technology Holdings LLC provide support to global entrepreneurs and new businesses. It offers managing and growing global ventures. The company was founded by Sachiko Kuno and Ryuji Ueno in 1999 and is headquartered in Bethesda, MD.

Sucampo Pharma LLC engages in the pharmaceutical product development. It develops the naturally occurring compound prostones, including lubiprostone under the brand Amitiza, which is used for the treatment of chronic constipation, chronic idiopathic constipation (CIC) in adults, and irritable bowel syndrome with constipation (IBS-C). The company is headquartered in Osaka, Japan.

Part of Mallinckrodt Plc, Sucampo Pharma Europe Ltd. is a British company that develops therapies for gastrointestinal, circulatory, and ophthalmic diseases. The company is based in London, UK. Sucampo Pharma Europe was acquired by Sucampo Pharmaceuticals LLC, part of Mallinckrodt Plc from February 14, 2018 on September 28, 2006.

VLP Therapeutics LLC operates as a biopharmaceutical company. The firm focuses on developing preventative and therapeutic vaccines, as well as next generation targeted antibody agents to treat cancer and infectious diseases, such as malaria, dengue fever, zika virus-based diseases, and autoimmune. The company was founded by Wataru Akahata, Ryuji Ueno, Sachiko Kuno, Kei S. Tolliver and Misako Nakata in 2012 and is headquartered in Gaithersburg, MD.